雷沙吉兰作为利鲁唑附加治疗肌萎缩侧索硬化患者的安全性和有效性:一项随机、双盲、平行组、安慰剂对照的2期试验
这项在德国15个中心进行的随机双盲安慰剂对照2期试验纳入252例肌萎缩侧索硬化患者,比较雷沙吉兰1mg/日联合利鲁唑100mg/日与安慰剂联合利鲁唑的疗效。主要终点生存时间两组无差异(HR 0.91,单侧97.5%CI -∞至1.34,p=0.31),雷沙吉兰安全性良好。事后分析提示雷沙吉兰可能延缓基线ALSFRS-R月下降斜率大于0.5分患者的疾病进展,需另一临床试验证实。
要点
- 雷沙吉兰1mg/日联合利鲁唑未延长肌萎缩侧索硬化患者生存时间(HR 0.91,p=0.31)。
- 雷沙吉兰耐受性良好,不良事件频率两组相当,多数与疾病进展相关。
- 事后分析提示雷沙吉兰可能延缓基线ALSFRS-R月下降斜率大于0.5分患者的进展,需另一临床试验证实。
核心结论
- 雷沙吉兰在肌萎缩侧索硬化患者中安全性良好;主要终点生存时间两组无差异,尽管事后分析提示雷沙吉兰可能延缓基线ALSFRS-R月下降斜率大于0.5分患者的疾病进展,这需另一临床试验证实。
研究设计与样本
- 随机、双盲、平行组、安慰剂对照2期试验,在德国15个运动神经元病网络(MND-NET)中心(大学医院或诊所)入组可能、很可能或确诊的肌萎缩侧索硬化患者。
- 纳入标准:年龄至少18岁,研究前36个月内有进行性无力起病,病程大于6个月且小于3年,最佳坐位慢肺活量至少50%。
- 4周筛选期后按1:1随机分配至雷沙吉兰1mg/日或安慰剂,均联合利鲁唑100mg/日,按起病部位(延髓或脊髓)和研究中心分层。
- 随机后2、6、12、18个月随访;主要终点为生存时间(死亡时间或研究截止日期即最后患者最后访视加14天)。
- 2013年7月2日至2014年11月11日筛选273例,随机252例(雷沙吉兰组127例,安慰剂组125例);意向治疗分析纳入雷沙吉兰组126例和安慰剂组125例。
主要发现
- 研究结束时生存概率:雷沙吉兰组0.43(95%CI 0.25-0.59,n=126),安慰剂组0.53(95%CI 0.43-0.62,n=125)。
- 估计效应量(风险比)为0.91(单侧97.5%CI -∞至1.34;p=0.31)。
- 雷沙吉兰耐受性良好,多数不良事件由肌萎缩侧索硬化疾病进展所致而非治疗。
- 最常见不良事件:吞咽困难(雷沙吉兰组32例[25%] vs 安慰剂组24例[19%])和呼吸衰竭(雷沙吉兰组25例[20%] vs 安慰剂组31例[25%])。
- 两组不良事件频率相当。
局限性
- 事后分析提示雷沙吉兰可能延缓基线ALSFRS-R月下降斜率大于0.5分患者的疾病进展,这需另一临床试验证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rasagiline, a monoamine oxidase B inhibitor with neuroprotective potential in Parkinson's disease, has shown a disease-modifying effect in the SOD1-Gly93Ala low-expressing mouse model of amyotrophic lateral sclerosis, both alone and in combination with riluzole. We sought to test whether or not rasagiline 1 mg/day can prolong survival in patients with amyotrophic lateral sclerosis also receiving riluzole. METHODS: Patients with possible, probable, or definite amyotrophic lateral sclerosis were enrolled to our randomised, placebo-controlled, parallel-group, double-blind, phase 2 trial from 15 German network for motor neuron diseases (MND-NET) centres (university hospitals or clinics). Eligible patients were aged at least 18 years, had onset of progressive weakness within the 36 months before the study, had disease duration of more than 6 months and less than 3 years, and had a best-sitting slow vital capacity of at least 50%. After a 4-week screening period, eligible patients were randomly assigned (1:1) to receive either rasagiline (1 mg/day) or placebo in addition to riluzole (100 mg/day), after stratification for site of onset (bulbar or spinal) and study centre. Patients and all personnel assessing outcome parameters were masked to treatment allocation. Patients were followed up 2, 6, 12, and 18 months after randomisation. The primary endpoint was survival time, defined as the time to death or time to study cutoff date (ie, the last patient's last visit plus 14 days). Analyses of primary outcome and safety measures were done in all patients who received at least one dose of trial treatment (intention-to-treat population). The trial is registered with ClinicalTrials.gov, number NCT01879241. FINDINGS: Between July 2, 2013, and Nov 11, 2014, 273 patients were screened for eligibility, and 252 patients were randomly assigned to receive rasagiline (n=127) or placebo (n=125). 126 patients taking rasagiline and 125 taking placebo were included in the intention-to-treat analysis. For the primary outcome, the survival probability at the end of the study was 0·43 (95% CI 0·25-0·59) in the rasagiline group (n=126) and 0·53 (0·43-0·62) in the placebo group (n=125). The estimated effect size (hazard ratio) was 0·91 (one-sided 97·5% CI -infinity to 1·34; p=0·31). Rasagiline was well tolerated, and most adverse events were due to amyotrophic lateral sclerosis disease progression rather than treatment; the most frequent of these were dysphagia (32 [25%] taking rasagiline vs 24 [19%] taking placebo) and respiratory failure (25 [20%] vs 31 [25%]). Frequency of adverse events were comparable between both groups. INTERPRETATION: Rasagiline was safe in patients with amyotrophic lateral sclerosis. There was no difference between groups in the primary outcome of survival, although post-hoc analysis suggested that rasagiline might modify disease progression in patients with an initial slope of Amyotrophic Lateral Sclerosis Functional Rating Scale Revised greater than 0·5 points per month at baseline. This should be confirmed in another clinical trial. FUNDING: Teva Pharmaceutical Industries.
引用
- Ludolph AC, Schuster J, Dorst J, et al. Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial. Lancet Neurol. 2018. PMID: 29934198. doi:10.1016/S1474-4422(18)30176-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。